5 Spam-Free Article(s) Found
Sort:
Date
Filter:
7d
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Why Merck (MRK) is Poised to Beat Earnings Estimates Again http://www.zacks.com/stock/news/853066/why-merck-mrk-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-853066 Apr 03, 2020 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates http://www.zacks.com/stock/news/853058/pharma-stock-roundup-jnj-snys-coronavirus-product-development-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-853058 Apr 03, 2020 - J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis http://www.zacks.com/stock/news/851267/heres-why-you-should-buy-lilly-stock-amid-coronavirus-crisis?cid=CS-ZC-FT-analyst_blog|rank_focused-851267 Apr 02, 2020 - Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/845194/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-845194 Mar 30, 2020 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
AstraZeneca's Imfinzi Gets FDA Nod for SCLC Label Expansion http://www.zacks.com/stock/news/845152/astrazenecas-imfinzi-gets-fda-nod-for-sclc-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-845152 Mar 30, 2020 - AstraZeneca's (AZN) Imfinzi gets FDA approval as first-line treatment for extensive-stage small cell lung cancer patients. A phase III study on Farxiga in CKD patients meets endpoint earlier than expected.

Pages: 1

Page 1